Last week, state officials in Michigan announced that research projects financed by the state’s adult-use marijuana program will assess the effects of medical cannabis in military veterans. The projects have been allocated $20 million, with $13 million of this amount being used to investigate the effectiveness of cannabis in preventing veteran suicide and treating the medical conditions that impact armed service veterans in the United States.
This grant, which was awarded to the Multidisciplinary Association for Psychedelic Studies (“MAPS”), will also finance a phase 2 study on the effectiveness of inhaled botanical cannabis in treating post-traumatic stress disorder (“PTSD”). The funds come from the state’s Veteran Cannabis Research Grant Program, which was established in 2018 by a legalization measure approved by voters.
For the study, researchers plan to recruit more than 300 veterans who will spend 35 or so days self-administering self-titrated inhaled doses of high-quality botanical marijuana. MAPS asserts that substance-use disorders, depression and PTSD contributed significantly to suicidality and were common disorders among veterans.
Berra Yazar-Klosinki, the chief scientific officer of the organization’s Public Benefit Corporation, stated that the grant provided the resources needed to align the body of scientific evidence with marijuana that was similar to what’s available in the state’s regulated marijuana programs.
Veterans have played a huge role in the fight against marijuana prohibition and encouraging more research on the therapeutic potential of other controlled substances, including psychedelics, to be conducted. If the study finds that smoked marijuana is effective in treating PTSD, phase 3 trials can begin, after which raw marijuana will be developed and sold as a pharmaceutical.
The remaining $7 million, which was allocated to the Bureau of Community Action and Economic Opportunity at Wayne State University, will be used to study how marijuana may be used to treat various mental health conditions, including depression, sleep disorders, anxiety and post-traumatic stress disorder. This project will look into the biochemical mechanisms through which marijuana could be used to treat suicidality, depression, sleep disorders, anxiety and PTSD.
Meanwhile, legislators in Washington are calling for an ease in restrictions on cannabis research through the Congressional infrastructure legislation, which includes a provision that would allow researchers to study marijuana from retailers in cannabis-legal states.
Additionally, the Senate Appropriations Committee recently approved an amendment that would promote veteran access to medical cannabis, by permitting physicians at the Department of Veterans Affairs in the United States to issue marijuana regulations in legal states.
As the medical use of cannabis grows, the market for precise dose-measuring devices such as the RYAH Smart Inhaler made by RYAH Group Inc. (CSE: RYAH) is growing rapidly since the device addresses a previously unmet need.
NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://cnw.fm/RYAH
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
